tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

Cong Xu, Ting Liang, Fangrong Zhang, Jing Liu, Yunfeng FuBMC Bioinformatics 2021 · DOI

TL;DR

This study identifies specific tRNA-derived fragments (tRFs/tiRNAs) that are differentially expressed in relapsed/refractory multiple myeloma (R/RMM) patients compared to newly diagnosed patients. These tRFs/tiRNAs show potential as biomarkers for R/RMM and may play roles in drug resistance, opening avenues for new therapeutic strategies.

What Problem Does This Paper Address?

Multiple myeloma (MM) is a challenging blood cancer characterized by its tendency to relapse and develop resistance to therapies. While non-coding RNAs (ncRNAs) have emerged as important players in cancer, the specific roles of tRNA-derived fragments (tRFs/tiRNAs) in MM progression, particularly in the context of relapse and drug resistance, remain largely unexplored. This knowledge gap hinders the development of novel diagnostic tools and therapeutic targets for R/RMM.

Methods

The researchers employed a multi-pronged approach:

  • RNA Sequencing (RNA-seq): High-throughput sequencing was used to profile the expression of tRFs/tiRNAs in bone marrow samples from newly diagnosed MM (NDMM) patients and relapsed/refractory MM (R/RMM) patients.
  • Quantitative Real-time PCR (qPCR): This technique was used to validate the RNA-seq findings for specific tRFs/tiRNAs in clinical samples and MM cell lines.
  • Bioinformatic Analysis:
    • Target Gene Prediction: Algorithms like TargetScan were used to predict the genes that tRFs/tiRNAs might regulate.
  • Functional Enrichment Analysis: DAVID Bioinformatics Resources were utilized for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to understand the biological functions associated with the predicted target genes.
  • Statistical Analysis: Standard statistical methods, including t-tests and Mann-Whitney tests, were applied to determine the significance of observed differences.

Datasets

  • Clinical Specimens: Bone marrow samples from 20 newly diagnosed MM (NDMM) patients and 22 relapsed/refractory MM (R/RMM) patients.
  • Cell Lines: MM cell lines (U266 and RPMI-8226) and their drug-resistant counterparts (U266/BTZ and RPMI-8226/BTZ) were used for validation.
  • Sequencing Data: RNA-seq data was generated and has been uploaded to the GEO database (accession number GSE171003).

Key Insights and Ideas

  • tRFs/tiRNAs as potential biomarkers: The study identified specific tRFs/tiRNAs that are significantly up- or down-regulated in R/RMM patients, suggesting their utility as biomarkers for this challenging subtype of MM.
  • Role in drug resistance: The observed differential expression of certain tRFs/tiRNAs in drug-resistant cell lines points towards their involvement in mediating resistance to MM therapies.
  • Functional implications: Bioinformatic analysis suggests that these tRFs/tiRNAs may influence key cellular processes such as transcription regulation, cell adhesion, and migration, which are critical in cancer progression.
  • Pathway involvement: The identified tRFs/tiRNAs appear to be involved in important signaling pathways like Ras signaling, PI3K-Akt, and FoxO signaling, which are known to play roles in cancer development and drug resistance.

Key Results

  • Differential Expression: High-throughput sequencing identified over 400 commonly expressed tRFs/tiRNAs. Under stringent criteria (fold change ≥ 1.5 and P<0.05), 10 tRFs/tiRNAs were found to be upregulated and 16 were downregulated in R/RMM compared to NDMM.
  • Validation of Key tRFs: qPCR confirmed the differential expression of selected tRFs/tiRNAs, with tRF-60:77-Thr-TGT-1 being significantly upregulated and tRF-1:22-Lys-TTT-1-M3 being downregulated in both R/RMM patients and drug-resistant MM cell lines.
  • Target Gene Analysis: tRF-60:77-Thr-TGT-1's predicted targets are implicated in membrane functions and transcription initiation, while tRF-1:22-Lys-TTT-1-M3's targets are mainly in the nucleoplasm and regulate transcription factor activity.

Limitations and Future Work

The authors acknowledge several limitations:

  • miRNA Regulation: tRFs/tiRNAs can also regulate miRNA activity, but current bioinformatics tools are insufficient to predict these interactions, preventing the construction of a comprehensive ceRNA network. Future work will explore this aspect through molecular biology experiments.
  • Cell Line Diversity: The study used only two MM cell lines for in vitro validation. While this is common practice, the authors suggest that using additional cell lines representing different MM subclasses would strengthen the findings.
  • Clinical Validation: While the study provides a strong foundation, further validation in larger, diverse patient cohorts is necessary to solidify the biomarker potential of these tRFs/tiRNAs.
  • Mechanistic Elucidation: The precise mechanisms by which these tRFs/tiRNAs exert their functions in MM progression and drug resistance require further in-depth investigation.

Summary updated

BibTeX
@article{xu2021trna,
  author = {Cong Xu and Ting Liang and Fangrong Zhang and Jing Liu and Yunfeng Fu},
  title = {{tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma}},
  journal = {BMC Bioinformatics},
  year = {2021},
  doi = {10.1186/s12859-021-04167-8},
}
Figure